102 related articles for article (PubMed ID: 21325666)
1. Apolipoprotein CIII: 42 years old and even more interesting.
Ginsberg HN; Brown WV
Arterioscler Thromb Vasc Biol; 2011 Mar; 31(3):471-3. PubMed ID: 21325666
[No Abstract] [Full Text] [Related]
2. Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia.
Caron S; Verrijken A; Mertens I; Samanez CH; Mautino G; Haas JT; Duran-Sandoval D; Prawitt J; Francque S; Vallez E; Muhr-Tailleux A; Berard I; Kuipers F; Kuivenhoven JA; Biddinger SB; Taskinen MR; Van Gaal L; Staels B
Arterioscler Thromb Vasc Biol; 2011 Mar; 31(3):513-9. PubMed ID: 21183731
[TBL] [Abstract][Full Text] [Related]
3. Role of apolipoprotein C-III overproduction in diabetic dyslipidaemia.
Adiels M; Taskinen MR; Björnson E; Andersson L; Matikainen N; Söderlund S; Kahri J; Hakkarainen A; Lundbom N; Sihlbom C; Thorsell A; Zhou H; Pietiläinen KH; Packard C; Borén J
Diabetes Obes Metab; 2019 Aug; 21(8):1861-1870. PubMed ID: 30972934
[TBL] [Abstract][Full Text] [Related]
4. Diabetic dyslipidemia and response to intensified glycemic treatment: why there are differences?
Baroni MG
J Endocrinol Invest; 2005 Nov; 28(10):869-70. PubMed ID: 16419487
[No Abstract] [Full Text] [Related]
5. Apolipoprotein-CIII O-Glycosylation Is Associated with Micro- and Macrovascular Complications of Type 2 Diabetes.
Naber A; Demus D; Slieker RC; Nicolardi S; Beulens JWJ; Elders PJM; Lieverse AG; Sijbrands EJG; 't Hart LM; Wuhrer M; van Hoek M
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791405
[TBL] [Abstract][Full Text] [Related]
6. Diabetes-accelerated atherosclerosis and inflammation.
Kanter JE; Averill MM; Leboeuf RC; Bornfeldt KE
Circ Res; 2008 Oct; 103(8):e116-7. PubMed ID: 18845812
[No Abstract] [Full Text] [Related]
7. Metformin primarily decreases plasma glucose not by gluconeogenesis suppression but by activating glucose utilization in a non-obese type 2 diabetes Goto-Kakizaki rats.
Yoshida T; Okuno A; Tanaka J; Takahashi K; Nakashima R; Kanda S; Ogawa J; Hagisawa Y; Fujiwara T
Eur J Pharmacol; 2009 Nov; 623(1-3):141-7. PubMed ID: 19765581
[TBL] [Abstract][Full Text] [Related]
8. From hyperglycemia to the risk of cardiovascular disease.
Leiter LA
Rev Cardiovasc Med; 2006; 7 Suppl 2():S3-9. PubMed ID: 17224875
[TBL] [Abstract][Full Text] [Related]
9. Association of serum apolipoprotein C III levels and apolipoprotein C III gene Sst I polymorphism with carotid intima-media thickness in Chinese type 2 diabetic patients.
Chen X; Tian H; Liu R
Diabetes Res Clin Pract; 2004 Oct; 66(1):41-7. PubMed ID: 15364160
[TBL] [Abstract][Full Text] [Related]
10. Disorders of glucose metabolism and risk of oral cancer.
Suba Z; Ujpál M
Fogorv Sz; 2007 Oct; 100(5):250-7, 243-9. PubMed ID: 18078144
[TBL] [Abstract][Full Text] [Related]
11. Medicine. Visfatin: a new adipokine.
Hug C; Lodish HF
Science; 2005 Jan; 307(5708):366-7. PubMed ID: 15604359
[No Abstract] [Full Text] [Related]
12. Editorial comment.
Ross LS
Urology; 2009 Sep; 74(3):559-60; author reply 560. PubMed ID: 19716906
[No Abstract] [Full Text] [Related]
13. Intrapulmonary administration of natural honey solution, hyperosmolar dextrose or hypoosmolar distill water to normal individuals and to patients with type-2 diabetes mellitus or hypertension: their effects on blood glucose level, plasma insulin and C-peptide, blood pressure and peaked expiratory flow rate.
Al-Waili N
Eur J Med Res; 2003 Jul; 8(7):295-303. PubMed ID: 12911866
[TBL] [Abstract][Full Text] [Related]
14. Metabolic memory: implications for diabetic vascular complications.
Cooper ME
Pediatr Diabetes; 2009 Aug; 10(5):343-6. PubMed ID: 19490497
[No Abstract] [Full Text] [Related]
15. Metabolomics as a functional genomic tool for understanding lipid dysfunction in diabetes, obesity and related disorders.
Griffin JL; Nicholls AW
Pharmacogenomics; 2006 Oct; 7(7):1095-107. PubMed ID: 17054419
[TBL] [Abstract][Full Text] [Related]
16. Type 2 diabetes mellitus is characterized by reduced postprandial adiponectin response: a possible link with diabetic postprandial dyslipidemia.
Annuzzi G; Bozzetto L; Patti L; Santangelo C; Giacco R; Di Marino L; De Natale C; Masella R; Riccardi G; Rivellese AA
Metabolism; 2010 Apr; 59(4):567-74. PubMed ID: 19922965
[TBL] [Abstract][Full Text] [Related]
17. [Apolipoprotein AI-CIII, B, and CII gene polymorphisms in patients with non-insulin dependent diabetes mellitus. Association with hyperlipemia].
Gutiérrez C; Vendrell J; Broch M; Pastor R; Llor C; Simón I; Richart C
Med Clin (Barc); 1996 Nov; 107(15):561-5. PubMed ID: 9064379
[TBL] [Abstract][Full Text] [Related]
18. [Adipokines and lipid metabolism in type 2 diabetes].
von Eynatten M; Hamann A
Dtsch Med Wochenschr; 2007 May; 132(19):1048-52. PubMed ID: 17476636
[No Abstract] [Full Text] [Related]
19. Nonobese, insulin-deficient Ins2Akita mice develop type 2 diabetes phenotypes including insulin resistance and cardiac remodeling.
Hong EG; Jung DY; Ko HJ; Zhang Z; Ma Z; Jun JY; Kim JH; Sumner AD; Vary TC; Gardner TW; Bronson SK; Kim JK
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1687-96. PubMed ID: 17911348
[TBL] [Abstract][Full Text] [Related]
20. Engineered glucagon-like peptide-1-producing hepatocytes lower plasma glucose levels in mice.
Riedel MJ; Lee CW; Kieffer TJ
Am J Physiol Endocrinol Metab; 2009 Apr; 296(4):E936-44. PubMed ID: 19190262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
